Bifogade filer
Interim Report Q2 2023
Prenumeration
Du har en aktiv prenumeration.
Prenumerera på pressmeddelanden från Magle Chemoswed via email.
Du prenumererar på följande språk.
Välj vilka språk du vill prenumerera på.
Modular Finance AB kommer att hantera vissa av dina personuppgifter om du väljer att prenumerera. Mer information om vår personuppgiftshantering finns här.
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
2023-07-18 08:30:00
Today, on 18 Julyl 2023, Magle Chemoswed Holding AB (publ) has published its interim report for Q2 2023.
APR-JUN 2023 KEY INDICATORS
- Net sales amounted to 38.1 MSEK (35.5).
- EBITDA equalled 9.5 MSEK (7.7).
- Operating profit (EBIT) is 6.3 MSEK (4.2)
- Profit after tax amounted to 4.7 MSEK (3.8)
- Earnings per share SEK 0,4 (0,4) per share
JAN-JUN 2023 KEY INDICATORS
- Net sales amounted to 76.7 MSEK (65.7).
- EBITDA equalled 17.0 MSEK (15.4).
- Operating profit (EBIT) is 10.6 MSEK (8.8)
- Profit after tax amounted to 7.6 MSEK (7.9)
- Earnings per share SEK 0,7 (0,7) per share
“In the second quarter, we expanded our project portfolio, strong clinical data for SmartPAN® was presented to key opinion leaders, and total revenues from our CDMO business and DSM-based products increased by 7.4 percent compared to the corresponding period last year.” says Justin Pierce, CEO of Magle Group.
The full report is available at https://maglegroup.com/financial-reports/